Fluticasone furoate successfully suppresses SAR symptoms

Once-daily intranasal fluticasone furoate [Allermist, Avamys] successfully suppresses nasal symptoms and ocular symptoms associated with seasonal allergic rhinitis (SAR), according to phase III data* presented at the 63rd Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI) [San Diego, California, US; February 2007]. The studies demonstrated that fluticasone furoate was effective in patients with SAR caused by ragweed or mountain cedar pollen, was well tolerated, and was effective and safe in children aged 2−11 years. Significant and clinically relevant improvements in rhinitis-associated quality of life (QOL) were also demonstrated in patients treated with fluticasone furoate.